Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Friedrich

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Mucosal Immunology|May 20, 2023
MHC class II antigen presentation by intestinal epithelial cells fine-tunes bacteria-reactive CD4 T-cell responsesCornelia E Heuberger, Alina Janney, Nicholas Ilott, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cellsRalf Lutterbuese, Tobias Raum, Roman Kischel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 18, 2009
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine releaseMaria Amann, Sandrine D'Argouges, Grit Lorenczewski, et al.
Molecular Cancer Therapeutics|August 11, 2021
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) MoleculeElizabeth Pham, Matthias Friedrich, Famke Aeffner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 2021
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissuesFrans V Suurs, Grit Lorenczewski, Julie M Bailis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2020
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon CancerSarah McCuaig, David Barras, Elizabeth H Mann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate CancerPetra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
Molecular Imaging of Radiolabeled Bispecific T-Cell Engager <sup>89</sup>Zr-AMG211 Targeting CEA-Positive TumorsStijn J H Waaijer, Frank J Warnders, Sabine Stienen, et al.
Oncoimmunology|September 18, 2018
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumorsMaxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, et al.
Blood Advances|September 4, 2020
AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeysRebecca L Goldstein, Ana Goyos, Chi-Ming Li, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Mucosal Immunology|May 20, 2023
MHC class II antigen presentation by intestinal epithelial cells fine-tunes bacteria-reactive CD4 T-cell responsesCornelia E Heuberger, Alina Janney, Nicholas Ilott, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cellsRalf Lutterbuese, Tobias Raum, Roman Kischel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 18, 2009
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine releaseMaria Amann, Sandrine D'Argouges, Grit Lorenczewski, et al.
Molecular Cancer Therapeutics|August 11, 2021
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) MoleculeElizabeth Pham, Matthias Friedrich, Famke Aeffner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 2021
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissuesFrans V Suurs, Grit Lorenczewski, Julie M Bailis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2020
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon CancerSarah McCuaig, David Barras, Elizabeth H Mann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate CancerPetra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
Molecular Imaging of Radiolabeled Bispecific T-Cell Engager <sup>89</sup>Zr-AMG211 Targeting CEA-Positive TumorsStijn J H Waaijer, Frank J Warnders, Sabine Stienen, et al.
Oncoimmunology|September 18, 2018
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumorsMaxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, et al.
Blood Advances|September 4, 2020
AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeysRebecca L Goldstein, Ana Goyos, Chi-Ming Li, et al.
Pageof 9